Raoult Didier, Fournier Pierre-Edouard, Vandenesch François, Mainardi Jean-Luc, Eykyn Susannah J, Nash James, James Edward, Benoit-Lemercier Catherine, Marrie Thomas J
Unité des Rickettsies, Faculté de Médecine, Université de la Méditerranée, 27 Boulevard Jean Moulin, 13385 Marseille CEDEX 05, France.
Arch Intern Med. 2003 Jan 27;163(2):226-30. doi: 10.1001/archinte.163.2.226.
Endocarditis caused by Bartonella species is a potentially lethal infection characterized by a subacute evolution and severe valvular lesions.
To evaluate the outcome of patients with Bartonella endocarditis and to define the best antibiotic regimen using the following measures: recovery, relapse, or death.
We performed a retrospective study on 101 patients who were diagnosed in our laboratory as having Bartonella endocarditis between January 1, 1995, and April 30, 2001. Bartonella infection was diagnosed using immunofluorescence with a 1:800 cutoff, polymerase chain reaction amplification of DNA, and/or culture findings of Bartonella species from whole blood, serum, and/or valvular biopsy specimens. A standardized questionnaire was completed by investigators for each patient.
Twelve of the 101 patients died and 2 relapsed. Patients receiving an aminoglycoside were more likely to fully recover (P =.02), and those treated with aminoglycosides for at least 14 days were more likely to survive than those with shorter therapy duration (P =.02).
Effective antibiotic therapy for Bartonella endocarditis should include an aminoglycoside prescribed for a minimum of 2 weeks.
巴尔通体属引起的心内膜炎是一种潜在致命性感染,其特征为亚急性进展和严重瓣膜病变。
使用以下指标评估巴尔通体心内膜炎患者的治疗结果,并确定最佳抗生素治疗方案:康复、复发或死亡。
我们对1995年1月1日至2001年4月30日期间在我们实验室诊断为巴尔通体心内膜炎的101例患者进行了回顾性研究。使用免疫荧光法(截断值为1:800)、DNA聚合酶链反应扩增以及从全血、血清和/或瓣膜活检标本中培养巴尔通体属的结果来诊断巴尔通体感染。研究人员为每位患者填写了一份标准化问卷。
101例患者中有12例死亡,2例复发。接受氨基糖苷类药物治疗的患者更有可能完全康复(P = 0.02),与治疗时间较短的患者相比,接受氨基糖苷类药物治疗至少14天的患者存活可能性更大(P = 0.02)。
巴尔通体心内膜炎的有效抗生素治疗应包括使用氨基糖苷类药物,且至少使用2周。